Outline. Update in the Fast Moving World of HIV HISTORY AND GLOBAL EPIDEMIOLOGY. When was the first report describing AIDS released?
|
|
- Charla Powell
- 6 years ago
- Views:
Transcription
1 Outline Update in the Fast Moving World of HIV April Advances in ID Monica Gandhi MD, MPH Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine Medical director, Ward 86 HIV Clinic, SFGH History of HIV Epidemiology: Global U.S. San Francisco HIV testing: When and how often? HIV Prevention: Where are we in 2015? HIV Treatment and a glimpse of the Cure Where are we in 2015? When was the first report describing AIDS released? 1. June 5, June 5, June 5, June 5, June 5, 1983 HISTORY AND GLOBAL EPIDEMIOLOGY 1
2 First Clinical Descriptions of AIDS MMWR Where did HIV come from? HIV lentivirus, subgroup of retroviruses Retroviruses means uses RNA as genetic material Lentivirus means SLOW virus (long interval between initial infection and onset of serious symptoms) Where did it come from? 5 major lineages of primate lentiviruses 1) Chimpanzees; gorillas 2) Monkeys; Mandrills 3) African green monkeys; baboons So major types of HIV closest to various SIV strains Pandemic strain (90% of world infections) HIV 1 Group M Group N Group O Group P SIV from chimpanzees SIV from gorillas HIV 2 7 subtypes (A G) SIV from sooty mangabeys 4) Sooty mangabeys 5) Sykes monkeys Hahn BH. AIDS as a Zoonosis: Scientific and Public Health Implications. Science
3 How did these viruses get from there to here? First theory The River The River: A Journey to the Source of HIV and AIDS (Edward Hooper, 1999) Polish scientist competing with Sabin for first oral polio vaccine (Sabin won) Scientist (Koprowski) administered his vaccine to 1 million people in Belgiumcontrolled Congo/ Rwanda/ Burundi anyway 1 Plotkin SA. CHAT oral polio vaccine was not the source of human immunodeficiency virus type 1 group M for humans. Clin. Infect. Dis 2001 Oral polio vaccines and HIV Theory refuted due to African green kidney monkey cells (not chimpanzee) used in making vaccines Timing problem Koprowskisues Rolling Stone for defamation (1992) gets $1 in damages What was the cross over event? Most common prevailing theory is the bushmeat tradehunting primates for food Hunters and other highly exposed populations: many SIV strains incorporated General human population one cross over event and SPREAD due to social disruption, colonization, city growth Hahn BH. AIDS as a Zoonosis: Scientific and Public Health Implications. Science 2000; 3
4 Bushmeat market in West & Central Africa % of HIV-positive persons in rural villages in Cameroon who report contact with wild animals and primates Hahn BH. AIDS as a Zoonosis: Scientific and Public Health Implications. Science 2000 LeBreton M..Wolfe ND. Exposure to wild primates among HIV infected persons. Emerg Infect. Di 2007 When did it get to us? Outbreak in region of origin difficult to distinguish from tropical diseases 1981 first description in U.S. Case report (Lancet, 1959) 25 year old man (naval seaman) Severely emaciated, Remorseless anal lesion, pneumonia, ulcer eating into upper lip Post mortem revealed cytomegalovirus and pneumocystis in the lungs Pathologists from Manchester Royal Infirmary (Lancet 1983) claimed his specimens were positive for HIV Methods questioned, apologies to fiancee demanded, no more tissue available To know when we need to go back in time and get human specimens! Oldest known stored specimens from Africa: 1213 plasma specimens from Leopoldville, Belgian Congo (now Kinshasa, Zaire DRC), U. of Washington HIV 1 found in 1 patient ( Bantu male, 1959) ZR59 strain intensely studied Phylogenetic analysis How much does this differ from SIV in chimpanzees? How much does ZR59 differ from modern HIV strains? Estimated HIV entered humans ~1930 4
5 Found another human specimen! Lymph node in paraffin found, adult female, Kinshasa, 1960 DRC60 DRC60 very different than ZR59 Family tree constructed, rate of mutation calculated Ancestor of HIV 1 M probably entered humans Worobey M. Direct evidence of extensive diversity of HIV 1 in Kinshasa by Nature 455 (October 2008) Population ( x 1000) Time to the most recent common ancestor ( ) period of HIV slow growth City, founding date Kinshasa The rest is West African history No city in region of crossspecies transmission before 1910 had population > 10,000 Kinshasa (and other) populations in 2 nd half of 20 th C. (trade, colonial) HIV 1 M from Cameroon brought by traveler down river to Kinshasa entered urban sexual network and spread By 1960 s, ~2000 people infected in Africa By 1970s, first probable outbreak in Kinshasa (OIs seen) Worobey M. Direct evidence of extensive diversity of HIV-1 in Kinshasa by Nature 10/08 What happened from there? Carried from West to Eastern Africa in 70 s Long distances between cities, difficulty in travel, violence, insecurity limited spread in W. Africa Spread fast in E. Africa (especially in areas bordering Lake Victoria), reached epidemic form in early 80 s Labor migration (35% truck drivers positive Uganda 88) High ratio of men urban centers Low status of women Low rates circumcision Sexually transmitted infections (STIs) Sex work (85% Nairobi sex workers infected by 86) By mid and late 80 s, on to sub Saharan Africa Tanzamroad between Tanzania and Zambia high prevalence in 88, devastating proportions in South Global HIV prevalence in adults, 1985 Piot P. Retrospective seroepidemiology of AIDS virus infection in Nairobi populations. Journal of Infectious Diseases 1987 UNAIDS/WHO
6 Global HIV prevalence in adults, 1995 Global HIV prevalence in adults, 2005 UNAIDS/WHO 1995 UNAIDS/WHO 2005 How many people are currently living with HIV worldwide? million million million million million 8 million (1990) Number of people living with HIV Estimated number of people living with HIV globally, million (2014) UNAIDS Nov Year 6
7 WHY PEOPLE LIVING WITH HIV ARE BEING LEFT BEHIND THE TOP 4 REASONS 01 Human rights violations, stigma and discrimination 02 Access to treatment and services 03 Gender-based inequalities 04 Criminalization and exclusion Number of People Living With HIV, millions Children (< 15 y) 2.6 Women 17.4* Adults 34.3 Total HIV prevalence in school boys & girls in rural South Africa (Grades 9 & 10) Age Group (years) HIV Prevalence (2010) % (95% Confidence Interval) Male (n=1252) Female (n= 1423) ( ) 2.6 ( ) Gender-based inequalities Infection rates among young women are twice as high as among young men in sub Saharan Africa.. In some settings, up to 45% of adolescent girls report that their first sexual experience was forced In sub Saharan Africa, only 15% of young women aged are aware of their HIV status ( ) (0-3.7) (0-3.9) 6.1 ( ) 13.6 ( ) 24.7 ( ) In LIMC, average HIV prevalence among sex workers is ~12%, with an OR for HIV infection of 13.5 compared to all women aged (violence and criminalization big contributors) Kharasany AB. AIDS Source: Res Hum Abdool Retroviruses. Karim Q, al Sex 2014; Transm Slide Infect 2014 courtesy Diane Havlir
8 U.S. AND SAN FRANCISCO EPIDEMIOLOGY 75.4% 24.6% Diagnoses of HIV Infection among Adults and Adolescents, by Sex and Race/Ethnicity, 2013 United States and 6 Dependent Areas U.S. Census 2013 estimates: 13.2% Black/African American 17.1% Hispanic/Latino 77.7% White Risks in U.S. women cluster with poverty, disempowerment HIV in women clusters with poverty 1,2 ; interpersonal violence 3 ; incarceration 4 7 ; self esteem, alcohol/drugs 8 Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting. a Hispanics/Latinos can be of any race. 1 Amidora. STDs 2006; 2 CDC Surveillance 2011; 3 Wyatt. Am J Public Health 2002; 4 Doherty. JAIDS 2009; 5 Doherty. Am J Public Health 2007; 6 Adimora. Am J Public Health 2007; 7 Khan. J Urban Health 2009; 8 Forna. J Natl Med Assoc
9 San Francisco: New HIV Diagnosis, Living HIV cases and Deaths Trends in New HIV Diagnosis for males by infection/100,000 persons 15,979 living with HIV 302 new diagnosis (still about 1 new infection a day) 177 deaths Persons of color disproportionately affected in San Francisco as well 2014 San Francisco Epidemiology Report August 2015, slide courtesy of Susan Scheer PhD and Diane Havlir MD 2014 San Francisco Epidemiology Report August 2015, slide courtesy of Susan Scheer PhD and Diane Havlir MD Getting to Zero in San Francisco Consortium Zero new HIV infections Zero HIV deaths Zero stigma and discrimination Website: Launched in 2013 by Diane Havlir MD and Susan Buchbinder MD; Now involves UCSF, DPH, Mayor s Office, community organizations, Supervisors, Kaiser, public, foundations (MAC); meetings and town halls, truly multidimensional consortium 9
10 How often should a patient be tested for HIV infection at SFGH? TESTING 1. Once, then every time the patient reports risk factors 2. Once every 2 years and with reported risk factors 3. Once yearly and with reported risk factors 4. Once every 6 months and with reported risk factors 5. Every admission CDC 9/21/06 risk-based to routine HIV screening in all health care settings yrs after patient notified (opt out screening assent inferred unless patient declines) 1. HIV testing for those high risk at least qyear No written consent, relaxed prevention counseling Pregnancy: Screen in 1 st trimester, repeat in 3 rd trimester if risk factors Routine testing still called grade C recommendation by USPSTF up to April 30, 2013 Branson BM et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings.mmwr Recomm Rep Sep 22;55(RR 14):1 17 ; 2 Wynia MK. Routine screening: informed consent, stigma and the waning of HIV exceptionalism. Am J Bioeth Jul Aug;6(4):5 8; 3 Burke RC et al. Why don't physicians test for HIV? A review of the US literature. AIDS U.S. Preventative Services Task Force Recommendations changed April 2013 Routine testing once for everyone age ( grade A recommendation) Paves way for coverage under ACA Repeat testing based for Those higher risk for HIV infection Those actively engaged in risky behavior Those living in high prevalence setting Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, April 30,
11 What is the most effective modality of HIV prevention? PREVENTION 1. Male and female condoms 2. Circumcision 3. HIV vaccine 4. Pre exposure prophylaxis 5. Treating HIV infected individuals Focus on pre exposure prophylaxis: PrEP Preexposure prophylaxis (PrEP) is giving an HIVnegative individual a pill (daily, or coitally?) to prevent HIV infection (studied: Tenofovir +/ emtricitabine) We know this works if the person takes it Recommended by the CDC, approved by FDA, recommended by WHO 7 major daily PrEP trials iprex [1] (N = 2499) Partners PrEP [2] (N = 4747) TDF2 [3] (N = 1219) Bangkok TFV Study [4] (N= 2413) FEM PrEP [5] (N = 2120) VOICE [6] (N = 5029) Population/Setting MSM, 11 sites in US, S. America, Africa, Thailand Serodiscordant couples in Africa Heterosexual males and females in Botswana IDU (use in last year) in Bangkok, 20% female High risk women, Africa High risk women, Africa Intervention Daily oral TDF/FTC Daily oral TDF Daily oral TDF/FTC Daily oral TDF/FTC Daily oral TDF Daily oral TDF/FTC Daily oral TDF Daily oral TDF/FTC 1% TFV gel Reduction in HIV Infection Rate, % 44% (95% CI 15 63%), no ciswomen 67% (44 81%) reduction with TDF; 75% (55 87%) reduction with TDF/FTC (more efficacious in women than men) 62% (22 83%) (underpowered for sex differences) Overall efficacy 49% ( %); Women 78.6% (p 0.03); men 37.6% (p 0.15) Study stopped early, no significant efficacy 1% TDF gel & daily oral TDF arm both stopped early (HR 0.34 gel with detectable drug) Daily TDF/FTC arm. no significant efficacy PROUD [7] MSM in U.K. PROUD 86% (64 96%) effective, no ciswomen PROUD: Daily 1. Grant RM. NEJM 2010; (immediate 2. Baeten vs JM, deferred) NEJM. 2012; 3. Thigpen MC. NEJM Choopanya K Lancet 2013: 5. Van Damme L. NEJM. 2012; 6. Marrazzo J. NEJM 2015; 7. McCormack Lancet 2015; 8. Molina. NEJM
12 30 % of Adults with PrEP Indication No. of Adults with PrEP Indication 600,000 TREATMENT , , , , , , , , , MSM PWID Hetero. Men Hetero. Women Slide courtesy of Catherine Koss MD 0 MSM PWID Hetero. Men Hetero. Women What are the recommendations to start treatment worldwide and in the U.S.? 1. Start HIV treatment when the CD4 count is <500 in U.S. and <350 globally 2. Start HIV treatment when CD4 <500 both sets of recommendations 3. Start HIV treatment regardless of CD4 in U.S. and <500 worldwide 4. Start HIV treatment regardless of CD4 worldwide When to start treatment for HIV? Recommendations NO LONGER differ by resources 12
13 When to Begin Treatment for asymptomatic patients - U.S. guidelines 3/27/12 & 2/13/13 When to Begin Treatment for asymptomatic patients WHO guidelines September 30, 2015 HIV Infection Prior to 3/12, start when CD4 count <500 HIV Infection Prior to 9/30/15, start when CD4 count <500 ART is recommended for all HIV positive individuals ART is recommended for all HIV positive individuals Universal ART policy adopted in San Francisco through HIV Division leadership (Havlir, Hare) and SFDPH January 2010 DHHS. Guidelines for the use of antiretroviral agents in HIV 1 infected adults and adolescents; Available at: May 2015 Prioritize CD4 <350 or stage 3, 4; pregnant and breastfeeding women; all children especially < 1 year World Health Organization. Guidelines on when to start antiretroviral therapy and on pre exposure prophylaxis for HIV. September 30, th Annual CCO HIV and Hepatitis C Symposium clinicaloptions.com START: Immediate vs Deferred ART International, randomized phase IV study 215 sites in 35 countries Randomized 1:1 ART-naive adults with CD4+ cell count > 500 cells/mm 3 (N = 4685) Immediate ART* Delayed ART* (until CD4+ cell count 350 cells/mm 3 ) Interim results: serious AIDS and non-aids events, n 41 Study stopped by data and safety monitoring board following results of interim analysis Risk of serious illness or death reduced by 53% with immediate ART Rates of serious AIDS-related and non AIDS-related events lower in immediate ART arm START NEJM *Any licensed ART allowed, according to national guidelines. 86 START NEJM START study Although rates of serious AIDSrelated events and serious non AIDS related events were both lower, risk reduction was more pronounced for the AIDS related events Benefits similar in low, mid and highincome countries START and IPERGAY endorsed by Anthony Fauci, NIAID director, today on WAD 13
14 How many single pill combinations for the treatment of HIV are there now? WHEN TO DELAY THERAPY Hardly EVER (TB meningitis, other space-occupying lesions with inflammation, cryptococcal meningitis) TFV/FTC/efavirenz, approved 2006 TFV/FTC/elvitegravir/ cobicistat, approved 2012 A new era TFV/FTC/rilpivirine, approved 2011 TAF/FTC/rilpivirine approved 4/4/16 TAF/FTC/elvitegravir/ cobicistat approved 11/5/15 ABC/3TC/dolutegravir, approved 8/22/2014 Many options... Fewer toxicities Nucleoside and nucleotide RTIs Zidovudine, AZT (Retrovir) Abacavir, ABC (Ziagen) Lamivudine, 3TC (Epivir) Didanosine, ddi (Videx) Stavudine, d4t (Zerit) Tenofovir, TFV (Viread) Emtricitabine, FTC (Emtriva) Combivir (AZT/3TC) Trizivir (AZT/3TC/ABC) Epzicom (3TC/ABC) Truvada (FTC/TFV) CCR5 receptor blocker Maroviroc (Selzentry) Integrase inhibitor Raltegravir (Isentress) Elvitegravir (EVG) Dolutegravir (DTG) NNRTI s: Delavirdine (DLV) Nevirapine, NVP (Viramune) Efavirenz, EFV (Sustiva) Etravirine (Intelence) Rilpivirine (Edurant) Fusion inhibitors: Enfuvirtide, ENF or T20 (Fuzeon) SPC (1 pill once daily) Atripla (EFV/FTC/TDF) Complera (RPV/FTC/TDF) Stribild (EVG/cobicistat/TDF/ FTC) Protease inhibitors: Indinavir, IDV (Crixivan) Saquinavir, SQV (Invirase, hgc) Nelfinavir, NFV (Viracept) Amprenavir, APV (Agenerase) Atazanavir, ATV(Reyataz) Fosamprenavir, FPV (Lexiva) Kaletra (lopinavir/ritonavir) Tipranavir (Aptivus) Darunavir (Prezista) Prezcobix (Darunavir/cobicistat) Evotaz (ATV/cobicistat) Triumeq (DTG/FTC/TFV) Genvoya (TAF/FTC/ELV/Cobi) Odefsey (TAF/FTC/RPV) 14
15 The Mississippi Baby Typical biphasic decay 28 month old child (now 37 mo) born at 35 weeks gestation (2.5kg) via NSVD Rapid HIV test positive in mother during labor (CD4 644; viral load 2423 copies/ml) No antiretrovirals in labor (precipitous delivery) HIV viral load (~20,000 copies/ml) at 30 hours of age AZT/3TC/NVP (usually 1 drug) started as prophylaxis by 31 hours of age (31 hrs 7d), therapeutic dose of NVP used; latter switched to LPV/r (protease inhibitor) (7d 18 months) after 1 week Persaud. NEJM 2013 Persaud. NEJM
16 What happened to baby? Mother and baby lost to follow up when baby 18 months old Baby off treatment Re appeared ~24 months Plasma HIV RNA remained undetectable (off therapy) Super low HIV DNA in PBMC, no infectious virus ( graveyard sequences) No Western blot reactivity for child (remains reactive for mother) Baby (~42 months) still negative (CROI March, 2014) Baby (nearly 4 yrs) on 7/10/14 announced to have HIV viremia (16,750 copies/ml) CD4+ T cells/mm Year RNA copies/ml 14 patients in France cured? Visconti trial 14 pts diagnosed with primary HIV infection (acute) late 90 s early 00s (12 pts symptoms) Started on standard ART < 10 weeks, continued x 3 years, then interrupted (6 9.6 years out) 14 patients ( post treatment controllers ) 8 with no detectable viremia off treatment (6/14 have occasional blips ) Early treatment meant low resting CD4 sets (but inducible) is this cure? Sáez Cirión A, Plos Pathogen 2013 Cure research initiative (Steve Deeks and team) Strategies being pursued Early ART may be curative Stem cell transplants to reduce reservoir Drugs to flush out HIV from latent reservoirs Vaccines to enhance host clearance Barriers anticipated Current ART not fully suppressive No high through put reliable assays to examine reservoir Flush out drugs may not work as monotherapy 16
HIV Update: Looking Forward, Where are we going? Outline
HIV Update: Looking Forward, Where are we going? 11 th HIV Network Nursing Conference May 15, 2015 Monica Gandhi MD, MPH Professor of Medicine and Medical Director ( Ward 86 ), Division of HIV/AIDS San
More informationOutline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? Updates in the fast moving field of HIV medicine EPIDEMIOLOGY
Updates in the fast moving field of HIV medicine 35 th Advances in Infectious Diseases April 25, 2014 Monica Gandhi MD, MPH Professor of Medicine and Clinic Director ( Ward 86 ), Division of HIV/AIDS San
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationOutline. HIV in 2017 GLOBAL EPIDEMIOLOGY. When was the first report describing AIDS released? Epidemiology: Global U.S.
Outline HIV in 2017 March 22, 2017 Advances in Infectious Diseases Monica Gandhi MD, MPH Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine Medical director, Ward 86 HIV Clinic,
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationHIV and Women. HIV Health Services Planning Council February 22, 2016
HIV and Women HIV Health Services Planning Council February 22, 2016 Power Point by Monica Gandhi MD, MPH Professor of Medicine, UCSF Division of HIV, Infectious Diseases, and Global Medicine Medical director,
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationPrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV
PrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV Laura Beauchamps, MD Assistant Professor Division of Infectious Diseases University of Mississippi Medical Center Principal Investigator
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationcontinuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationHIV/AIDS HIV/AIDS: Outline. Morbidity and Mortality Weekly Report (MMWR)
HIV/AIDS: Outline HIV/AIDS 2013 Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell University New York City January 31, 2013 Epidemiology
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationFundamentals of Antiretroviral Therapy
Fundamentals of Antiretroviral Therapy Southeast AIDS Education & Training Center HIV Clinical Overview 12 May 2016 Todd Hulgan, MD, MPH Department of Medicine, Division of Infectious Diseases Vanderbilt
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationMidwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationWorld AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary
World AIDS Day 2014 Year-by-Year Milestones in HIV/AIDS (Adapted from The POZ Timeline: Milestones in the HIV/AIDS Pandemic with additions compiled by Eric Brus, Director of HIV Health Promotion, AIDS
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationJonathan Cohn MD Wayne State University July 24,
Jonathan Cohn MD Wayne State University July 24, 2017 www.matecmichigan.org jcohn@med.wayne.edu Current HIV Test Sequence 4 th Generation Ag/Ab Combo > Differentiation Assay Abbott Architect Alere Determine
More informationMatters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationHIV in the United States: At A Glance
HIV / AIDS Overview HIV in the United States: At A Glance November 2013 Fast Facts More than 1.1 million people in the United States are living with HIV infection, and almost 1 in 6 (15.8%) are unaware
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationOverview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research
Overview of HIV Christina Polyak, MD, MPH Research Physician U.S. Military HIV Research Program, Walter Reed Army Institute of Research The views expressed are those of the authors and should not be construed
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationDominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis
Dominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis Charpentier, Harm Reduction Services Branch, Hawaii
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationNew Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationDr Valérie Martinez-Pourcher
Educa&ng Nurses About An&retrovirals and HIV Preven&on - State of the Science, Uptake Challenges, and Barriers Dr Valérie Martinez-Pourcher Pitié-Salpêtrière Hospital Paris We need to control HIV replication
More informationGaps between Policy and Practice in Managing HIV disease in Asia Pacific
Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Dr. N. Kumarasamy Chief Medical Officer YRGCARE Medical Centre Voluntary Health Services Chief-Chennai Antiviral Research and Treatment
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More informationHuman Immunodeficiency Virus (HIV)
HIV INFECTION! Human Immunodeficiency Virus (HIV) Infects human cells and causes gradual loss of immune system function, and these immune alterations predispose to the opportunistic infections, neoplasms,
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationNON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days
NON-OCCUPATIONAL POST EXPOSURE PREVENTION when you think you were exposed to hiv within the past three days A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY
More information